‘HPP is an organised, experienced team with an unprecedented focus on communication and collaboration. They coordinate activity with a flexible approach to the fluctuations in needs of project tasks and participants, while maintaining momentum toward the objective at hand. They are detail-oriented and timely with responses, and they truly comprehend the perspectives of stakeholders with whom they work in any given aspect of health policy research and strategy.’
The progressive form of non‑alcoholic fatty liver disease, known as non‑alcoholic steatohepatitis (NASH), is a growing concern as the global prevalence of obesity and type 2 diabetes continues to rise.
Genetic mutations in the BRCA1 and BRCA2 genes are associated with a significant risk of developing breast cancer, but many people who may carry these mutations cannot access genetic testing.
Atrial fibrillation is a common condition and leading cause of stroke, yet is widely under-recognised and people across Europe face significant inequalities in access to detection and treatment.